鹰瞳科技-B2025年年度报告

Beijing Airdoc Technology Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)Stock Code: 2251 ANNUAL REPORT 目錄 Corporate Information2Financial Summary5Chairman’s Statement6Management Discussion and Analysis13Profiles of Directors, Supervisors and SeniorManagement87Corporate Governance Report96Report of the Directors131Report of the Supervisors185Independent Auditor’s Report189Consolidated Statement of Profit or Loss200Consolidated Statement of Comprehensive Income201Consolidated Statement of Financial Position202Consolidated Statement of Changes in Equity204Consolidated Statement of Cash Flows206Notes to the Consolidated Financial Statements210Definitions and Glossary of Technical Terms359 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors 20257 2920256 27 Mr. ZHANG Dalei()(Chairman and chief executive officer)Ms. WANG Lin()Dr. HE Chao()(resigned on 29 July 2025)Mr. QIN Yong()Mr. WEI Yubo()(appointed on 27 June 2025) Independent Non-executive Directors Dr. WU Yangfeng()Dr. HUANG Yanlin()Mr. NG Ho Yin Owen() SUPERVISORS Mr. WEI Yubo()(resigned on 26 May 2025)Ms. BAI Huihui()Dr. LUO Ting()Ms. LUO Yujie()(appointed on 26 May 2025) 20255 2620255 26 AUDIT COMMITTEE Mr. NG Ho Yin Owen()(Chairman)Dr. HUANG Yanlin()Dr. WU Yangfeng() REMUNERATION AND APPRAISALCOMMITTEE Dr. HUANG Yanlin()(Chairman)Mr. NG Ho Yin Owen()Ms. WANG Lin() NOMINATION COMMITTEE 20257 2920257 2920257 29 Mr. ZHANG Dalei()(Chairman)(ceased on 29 July 2025)Dr. HUANG Yanlin()(Chairman)(effective from 29 July 2025)Dr. WU Yangfeng()Ms. WANG Lin()(effective from 29 July 2025) STRATEGY COMMITTEE Mr. ZHANG Dalei()(Chairman)Mr. NG Ho Yin Owen()Dr. WU Yangfeng() ESG COMMITTEE 20257 2920257 29 Mr. ZHANG Dalei()(Chairman)Ms. WANG Lin()Mr. QIN Yong()(effective from 29 July 2025)Dr. HE Chao()(ceased on 29 July 2025) AUTHORIZED REPRESENTATIVES Mr. ZHANG Dalei()Ms. SO Lai Shan() JOINT COMPANY SECRETARIES 20251 2020251 20 Ms. YANG Wenting()(ceased on 20 January 2025)Ms. WANG Xinfeng()(effective from 20 January 2025)Ms. SO Lai Shan()(ACG (CS, CGP) HKACG (CS, CGP)) HEAD OFFICE, REGISTERED OFFICE ANDPRINCIPAL PLACE OF BUSINESS INTHE PRC 22421 Room 21, 4/F., Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS INHONG KONG 33191901 Room 1901, 19/F., Lee Garden One33 Hysan AvenueCauseway BayHong Kong CORPORATE INFORMATION H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F., Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER 12151501 Kwok Yih & ChanSuite 1501, 15/F. Bank of America Tower12 Harcourt RoadCentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F., South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR Ernst & Young 97927 Certified Public AccountantsRegistered Public Interest Entity Auditor under theAccounting and Financial Reporting Council Ordinance27/F., One Taikoo Place979 King’s RoadQuarry BayHong Kong STOCK CODE 22512251 www.airdoc.com COMPANY WEBSITE www.airdoc.com FINANCIAL SUMMARY財務概要 A summary of the results and of the assets and liabilities ofthe Group for the last five financial years, as extracted fromthe audited financial information and financial statements isset out below: CHAIRMAN’S STATEMENT Dear Shareholders, Airdoc202512 31 On behalf of the Board of Directors of Beijing AirdocTechnology Development Co., Limited (the “Company” or“Airdoc”, together with its subsidiaries, the “Group”), I amp l e a s e d t o p r e s e n t t o y o u t h e G r o u p ’ s b u s i n e s sdevelopment and operating results for the year ended 31December 2025. I would like to extend my sincereappreciation for your trust in, and support for, the Company. 2025+A I(PBM-AI)AI (Retina-AI)AI (Neuro-AI) In 2025, the Group entered into a critical year to furtherdeepen its strategic transformation and accelerate high-quality development. Against the backdrop of the industryupgrade and market changes in the healthcare sector, theGroup has remained committed to its core strategy of“ t e c h n o l o g y - d r i v e np r o d u c t s+m u l t i - s c e n a r i oimplementation”. Leveraging our self-developed “WanYu”() medical-specific large language model as thetechnological foundation, the Group has deepened its focuson three core product lines, namely Myopia Prevention andControl AI (PBM-AI), Retina Detection AI (Retina-AI), andStress Resistance Monitoring AI (Neuro-AI). Through thisapproach, the Group achieved significant improvements inboth business quality and efficiency, while continuouslyrefining its strategic positioning.In addition,the Groupdelivered a series of solid achievements across technologyinnovation, product deployment and commercialisationefforts. CHAIRMAN’S STATEMENT AIToken7,99277%251415604 In the area of technological innovation, the Group’s R&Dstrategy has transitioned from a “scale investment-driven” toan “efficien